Skip to main content
Top
Published in: Hepatology International 3/2021

01-06-2021 | Fatty Liver | Original Article

Liver disease prevalence and severity in people with serious mental illness: a cross-sectional analysis using non-invasive diagnostic tools

Authors: Michael Rudi Braude, Danny Con, John Lubel, Abhijit Bidwai, Hoang-Thy Nguyen, Shipra Sharmamiglani, David Clarke, Anouk Dev, William Sievert

Published in: Hepatology International | Issue 3/2021

Login to get access

Abstract

Background/purpose of the study

Little is known about all-cause liver disease in people with serious mental illness (SMI), despite heightened risk factors. We, therefore, prospectively assessed liver disease by etiology and severity in a cross-sectional cohort of people with SMI at a tertiary health service.

Methods

We recruited 255 people with SMI between August 2019 and March 2020. Liver disease data were derived from structured interview, medical records, biochemical and BBV serological analyses, and vibration-controlled transient elastography (VCTE). Steatosis was determined using a threshold of ≥ 248 db/m via the controlled attenuation parameter (CAP) on VCTE. Liver disease prevalence was assessed descriptively, and predictors of metabolic-dysfunction associated fatty liver disease (MAFLD) analyzed using linear regression and multivariable analysis. Best fit modeling of non-invasive screening tests for MAFLD was also assessed.

Results

Valid VCTE was obtained for 252 (98.9%) participants. Median age was 40 years (IQR 31–49) with male predominance (65.9%). Hepatitis C Virus (HCV) seroprevalence was 14.7% (37/252), with four new viremic cases identified. Hepatic steatosis was diagnosed in 61.5% (155/252) of participants, with MAFLD criteria met in 59.9% (151/252) of cases. Clozapine and paliperidone were associated with hepatic steatosis (CAP + 23.3 db/m, p 0.013 and CAP + 25.5, p 0.037, respectively). Advanced liver disease, defined by LSM ≥ 8.2 kPa, was identified in 26 individuals (10.3%). MAFLD compared to no MAFLD was associated with more advanced liver disease (5.3 kPa, 4.3–6.5 versus 4.9 kPa, 3.9–5.6, p < 0.001).

Conclusion

Liver disease is common in people with SMI and should be screened for as part of standard physical health assessment.

Graphic abstract

Appendix
Available only for authorised users
Literature
1.
go back to reference Hughes E, Bassi S, Gilbody S, Bland M, Martin F. Prevalence of HIV, hepatitis B, and hepatitis C in people with severe mental illness: a systematic review and meta-analysis. Lancet Psychiatry 2016;3(1):40–48CrossRef Hughes E, Bassi S, Gilbody S, Bland M, Martin F. Prevalence of HIV, hepatitis B, and hepatitis C in people with severe mental illness: a systematic review and meta-analysis. Lancet Psychiatry 2016;3(1):40–48CrossRef
2.
go back to reference Regier DA, Farmer ME, Rae DS, Locke BZ, Keith SJ, Judd LL, et al. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA 1990;264(19):2511–2518CrossRef Regier DA, Farmer ME, Rae DS, Locke BZ, Keith SJ, Judd LL, et al. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA 1990;264(19):2511–2518CrossRef
3.
go back to reference Carrier P, Debette-Gratien M, Girard M, Jacques J, Nubukpo P, Loustaud-Ratti V, et al. Liver illness and psychiatric patients. Hepat Mon 2016;16(12):e41564CrossRef Carrier P, Debette-Gratien M, Girard M, Jacques J, Nubukpo P, Loustaud-Ratti V, et al. Liver illness and psychiatric patients. Hepat Mon 2016;16(12):e41564CrossRef
4.
go back to reference Byrne CD, Targher G. NAFLD: a multisystem disease. J Hepatol 2015;62(1 Suppl):S47–S64CrossRef Byrne CD, Targher G. NAFLD: a multisystem disease. J Hepatol 2015;62(1 Suppl):S47–S64CrossRef
5.
go back to reference Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M, et al. Global epidemiology of nonalcoholic fatty liver disease—meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016;64(1):73–84CrossRef Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M, et al. Global epidemiology of nonalcoholic fatty liver disease—meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016;64(1):73–84CrossRef
6.
go back to reference Sokal J, Messias E, Dickerson FB, Kreyenbuhl J, Brown CH, Goldberg RW, et al. Comorbidity of medical illnesses among adults with serious mental illness who are receiving community psychiatric services. J Nerv Ment Dis 2004;192(6):421–427CrossRef Sokal J, Messias E, Dickerson FB, Kreyenbuhl J, Brown CH, Goldberg RW, et al. Comorbidity of medical illnesses among adults with serious mental illness who are receiving community psychiatric services. J Nerv Ment Dis 2004;192(6):421–427CrossRef
7.
go back to reference Piatt EE, Munetz MR, Ritter C. An examination of premature mortality among decedents with serious mental illness and those in the general population. Psychiatr Serv 2010;61(7):663–668CrossRef Piatt EE, Munetz MR, Ritter C. An examination of premature mortality among decedents with serious mental illness and those in the general population. Psychiatr Serv 2010;61(7):663–668CrossRef
8.
go back to reference Adams LA, Anstee QM, Tilg H, Targher G. Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases. Gut 2017;66(6):1138–1153CrossRef Adams LA, Anstee QM, Tilg H, Targher G. Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases. Gut 2017;66(6):1138–1153CrossRef
9.
go back to reference Parabiaghi A, Bonetto C, Ruggeri M, Lasalvia A, Leese M. Severe and persistent mental illness: a useful definition for prioritizing community-based mental health service interventions. Soc Psychiatry Psychiatr Epidemiol 2006;41(6):457–463CrossRef Parabiaghi A, Bonetto C, Ruggeri M, Lasalvia A, Leese M. Severe and persistent mental illness: a useful definition for prioritizing community-based mental health service interventions. Soc Psychiatry Psychiatr Epidemiol 2006;41(6):457–463CrossRef
10.
go back to reference Bedogni G, Bellentani S, Miglioli L, Masutti F, Passalacqua M, Castiglione A, et al. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol 2006;6:33CrossRef Bedogni G, Bellentani S, Miglioli L, Masutti F, Passalacqua M, Castiglione A, et al. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol 2006;6:33CrossRef
11.
go back to reference Eslam M, Newsome PN, Anstee QM, Targher G, Gomez MR, Zelber-Sagi S, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol 2020;73(1):202–209CrossRef Eslam M, Newsome PN, Anstee QM, Targher G, Gomez MR, Zelber-Sagi S, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol 2020;73(1):202–209CrossRef
12.
go back to reference Karlas T, Petroff D, Sasso M, Fan JG, Mi YQ, de Lédinghen V, et al. Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis. J Hepatol 2017;66(5):1022–1030CrossRef Karlas T, Petroff D, Sasso M, Fan JG, Mi YQ, de Lédinghen V, et al. Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis. J Hepatol 2017;66(5):1022–1030CrossRef
13.
go back to reference Eddowes PJ, Sasso M, Allison M, Tsochatzis E, Anstee QM, Sheridan D, et al. Accuracy of fibroscan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease. Gastroenterology 2019;156(6):1717–1730CrossRef Eddowes PJ, Sasso M, Allison M, Tsochatzis E, Anstee QM, Sheridan D, et al. Accuracy of fibroscan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease. Gastroenterology 2019;156(6):1717–1730CrossRef
16.
go back to reference De Hert M, Cohen DA, Bobes J, Cetkovich-Bakmas M, Leucht S, Ndetei DM, et al. Physical illness in patients with severe mental disorders. II. Barriers to care, monitoring and treatment guidelines, plus recommendations at the system and individual level. World Psychiatry 2011;10(2):138–151CrossRef De Hert M, Cohen DA, Bobes J, Cetkovich-Bakmas M, Leucht S, Ndetei DM, et al. Physical illness in patients with severe mental disorders. II. Barriers to care, monitoring and treatment guidelines, plus recommendations at the system and individual level. World Psychiatry 2011;10(2):138–151CrossRef
17.
go back to reference Farrell A, Magliano D, Shaw J, Thompson A, Croagh C, Ryan M, et al. Non-alcoholic fatty liver disease is a big problem in Australia: analysis from the AusDiab cohort [Abstract]. J Gastroenterol Hepatol 2020;35(Suppl. 1):34–104 Farrell A, Magliano D, Shaw J, Thompson A, Croagh C, Ryan M, et al. Non-alcoholic fatty liver disease is a big problem in Australia: analysis from the AusDiab cohort [Abstract]. J Gastroenterol Hepatol 2020;35(Suppl. 1):34–104
18.
go back to reference Petta S, Di Marco V, Pipitone RM, Grimaudo S, Buscemi C, Craxì A, et al. Prevalence and severity of nonalcoholic fatty liver disease by transient elastography: genetic and metabolic risk factors in a general population. Liver Int 2018;38(11):2060–2068CrossRef Petta S, Di Marco V, Pipitone RM, Grimaudo S, Buscemi C, Craxì A, et al. Prevalence and severity of nonalcoholic fatty liver disease by transient elastography: genetic and metabolic risk factors in a general population. Liver Int 2018;38(11):2060–2068CrossRef
19.
go back to reference Teeratorn N, Piyachaturawat P, Thanapirom K, Chaiteerakij R, Sonsiri K, Komolmit P, et al. Screening for non-alcoholic fatty liver disease in community setting: a cohort study using controlled attenuation parameter-transient elastography. JGH Open 2020;4(2):245–250CrossRef Teeratorn N, Piyachaturawat P, Thanapirom K, Chaiteerakij R, Sonsiri K, Komolmit P, et al. Screening for non-alcoholic fatty liver disease in community setting: a cohort study using controlled attenuation parameter-transient elastography. JGH Open 2020;4(2):245–250CrossRef
20.
go back to reference Yan J, Hou C, Liang Y. The prevalence and risk factors of young male schizophrenics with non-alcoholic fatty liver disease. Neuropsychiatr Dis Treat 2017;13:1493–1498CrossRef Yan J, Hou C, Liang Y. The prevalence and risk factors of young male schizophrenics with non-alcoholic fatty liver disease. Neuropsychiatr Dis Treat 2017;13:1493–1498CrossRef
21.
go back to reference Mahady SE, Gale J, Macaskill P, Craig JC, George J, et al. Prevalence of elevated alanine transaminase in Australia and its relationship to metabolic risk factors: a cross-sectional study of 9,447 people. J Gastroenterol Hepatol 2017;32(1):169–176CrossRef Mahady SE, Gale J, Macaskill P, Craig JC, George J, et al. Prevalence of elevated alanine transaminase in Australia and its relationship to metabolic risk factors: a cross-sectional study of 9,447 people. J Gastroenterol Hepatol 2017;32(1):169–176CrossRef
22.
go back to reference Soliman HM, Wagih HM, Algaidi SA, Hafiz AH. Histological evaluation of the role of atypical antipsychotic drugs in inducing non-alcoholic fatty liver disease in adult male albino rats (light and electron microscopic study). Folia Biol (Praha) 2013;59(5):173–180 Soliman HM, Wagih HM, Algaidi SA, Hafiz AH. Histological evaluation of the role of atypical antipsychotic drugs in inducing non-alcoholic fatty liver disease in adult male albino rats (light and electron microscopic study). Folia Biol (Praha) 2013;59(5):173–180
23.
go back to reference Weston-Green K, Babic I, De Santis M, Pan B, Montgomery MK, Mitchell T, et al. Disrupted sphingolipid metabolism following acute clozapine and olanzapine administration. J Biomed Sci 2018;25(1):40CrossRef Weston-Green K, Babic I, De Santis M, Pan B, Montgomery MK, Mitchell T, et al. Disrupted sphingolipid metabolism following acute clozapine and olanzapine administration. J Biomed Sci 2018;25(1):40CrossRef
24.
go back to reference Morlán-Coarasa MJ, Arias-Loste MT, de la Foz VO, Martínez-García O, Alonso-Martín C, Crespo J, et al. Incidence of non-alcoholic fatty liver disease and metabolic dysfunction in first episode schizophrenia and related psychotic disorders: a 3-year prospective randomized interventional study. Psychopharmacology 2016;233(23–24):3947–3952CrossRef Morlán-Coarasa MJ, Arias-Loste MT, de la Foz VO, Martínez-García O, Alonso-Martín C, Crespo J, et al. Incidence of non-alcoholic fatty liver disease and metabolic dysfunction in first episode schizophrenia and related psychotic disorders: a 3-year prospective randomized interventional study. Psychopharmacology 2016;233(23–24):3947–3952CrossRef
25.
go back to reference Teff KL, Rickels MR, Grudziak J, Fuller C, Nguyen HL, Rickels K, et al. Antipsychotic-induced insulin resistance and postprandial hormonal dysregulation independent of weight gain or psychiatric disease. Diabetes 2013;62(9):3232–3240CrossRef Teff KL, Rickels MR, Grudziak J, Fuller C, Nguyen HL, Rickels K, et al. Antipsychotic-induced insulin resistance and postprandial hormonal dysregulation independent of weight gain or psychiatric disease. Diabetes 2013;62(9):3232–3240CrossRef
28.
go back to reference Lin S, Huang J, Wang M, Kumar R, Liu Y, Liu S, et al. Comparison of MAFLD and NAFLD diagnostic criteria in real world. Liver Int 2020;40(9):2082–2089CrossRef Lin S, Huang J, Wang M, Kumar R, Liu Y, Liu S, et al. Comparison of MAFLD and NAFLD diagnostic criteria in real world. Liver Int 2020;40(9):2082–2089CrossRef
29.
go back to reference Dulai PS, Singh S, Patel J, Soni M, Prokop LJ, Younossi Z, et al. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis. Hepatology 2017;65(5):1557–1565CrossRef Dulai PS, Singh S, Patel J, Soni M, Prokop LJ, Younossi Z, et al. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis. Hepatology 2017;65(5):1557–1565CrossRef
Metadata
Title
Liver disease prevalence and severity in people with serious mental illness: a cross-sectional analysis using non-invasive diagnostic tools
Authors
Michael Rudi Braude
Danny Con
John Lubel
Abhijit Bidwai
Hoang-Thy Nguyen
Shipra Sharmamiglani
David Clarke
Anouk Dev
William Sievert
Publication date
01-06-2021
Publisher
Springer India
Published in
Hepatology International / Issue 3/2021
Print ISSN: 1936-0533
Electronic ISSN: 1936-0541
DOI
https://doi.org/10.1007/s12072-021-10195-6

Other articles of this Issue 3/2021

Hepatology International 3/2021 Go to the issue